On January 20, 2021 VECT-HORUS, a biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, reported that it has just closed its Series D fund-raising (Press release, Vect-Horus, JAN 20, 2021, View Source [SID1234574137]). The first round, held in September 2020, raised €6.7 million and a second round in December 2020 added €5.3 million from private investors, bringing the total amount raised in these two rounds to €12 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This second funding round strengthens the company’s capital so it can pursue its ambitious programmes, focusing on identifying new vectors, developing theragnostic (therapeutic and diagnostic) agents in a clinical setting and validating its technology for delivering therapeutic antibodies and nucleic acids.

The health crisis has for the first time highlighted the enormous therapeutic potential (in terms of vaccination) of messenger RNAs (mRNAs) encapsulated in lipid nanoparticles. These mRNAs are used to express proteins of interest in the body. In contrast, antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) inhibit the expression of a particular gene and therefore the corresponding protein.
Using the company’s VECTrans platform, nanoparticles of mRNA, as well as ASOs and siRNAs, can be vectorized in order to treat both diseases with a genetic component and cancers.

’Very promising in vivo results have been obtained, for example on skeletal muscle. This means that there is a great potential for our technology to transport nucleic acids and to treat muscular pathologies,’ said Alexandre Tokay, Chairman of VECT-HORUS.

These developments are examples of the agility of the VECT-HORUS teams and its dual economic model, based both on developing proprietary molecules and the availability of its VECTrans technology to pharmaceutical and biotech partners to offer new methods for developing tomorrow’s therapeutic solutions.